Vise Technologies Inc. Invests $584,000 in Puma Biotechnology, Inc. $PBYI

Vise Technologies Inc. bought a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 72,030 shares of the biopharmaceutical company’s stock, valued at approximately $584,000.

Other large investors have also recently bought and sold shares of the company. Barclays PLC increased its holdings in Puma Biotechnology by 1.9% in the 4th quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 1,553 shares during the period. Cerity Partners LLC raised its position in Puma Biotechnology by 18.2% during the 4th quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 1,862 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares during the period. Kathmere Capital Management LLC lifted its stake in Puma Biotechnology by 9.8% during the 1st quarter. Kathmere Capital Management LLC now owns 29,779 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 2,648 shares during the period. Finally, Baron Wealth Management LLC boosted its holdings in shares of Puma Biotechnology by 8.2% in the 1st quarter. Baron Wealth Management LLC now owns 38,278 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 2,886 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, TD Cowen upped their price target on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Insider Activity

In related news, Director Allison Dorval sold 11,610 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $83,592.00. Following the sale, the director owned 90,780 shares in the company, valued at approximately $653,616. This trade represents a 11.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay M. Moyes sold 22,000 shares of Puma Biotechnology stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.22, for a total transaction of $158,840.00. Following the completion of the transaction, the director directly owned 58,322 shares of the company’s stock, valued at $421,084.84. The trade was a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 132,028 shares of company stock valued at $1,006,711 in the last three months. Corporate insiders own 22.20% of the company’s stock.

Puma Biotechnology Trading Down 1.3%

Shares of PBYI stock opened at $9.12 on Tuesday. Puma Biotechnology, Inc. has a twelve month low of $4.30 and a twelve month high of $9.51. The stock has a market cap of $470.77 million, a P/E ratio of 17.54 and a beta of 1.22. The stock has a 50 day moving average of $8.23 and a 200 day moving average of $7.37.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%. On average, research analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.